Ervahanine C






Names

    • Ervahanine C

Attributes

  • Canonical SMILES

    C/C=C1CN(C2CC3=C([C@@](CC\1[C@]2([H])C(OC)=O)([H])C4=CC=CC5=C4NC6=C5CCN(C7)[C@]8([H])[C@@](CC)([H])CC7C[C@]68C(OC)=O)NC9=C3C=CC=C9)C

  • InChI

    InChI=1S/C42H50N4O4/c1-6-24-17-23-20-42(41(48)50-5)38-29(15-16-46(21-23)39(24)42)27-12-10-13-28(36(27)44-38)31-18-30-25(7-2)22-45(3)34(35(30)40(47)49-4)19-32-26-11-8-9-14-33(26)43-37(31)32/h7-14,23-24,30-31,34-35,39,43-44H,6,15-22H2,1-5H3/b25-7+/t23?,24-,30?,31-,34?,35+,39-,42+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 90.66
  • #RotBonds: 4
  • MW: 674.8860000000003
  • HBD: 2
  • HBA: 6
  • logP: 6.480300000000007
  • Chemical Formula: C42H50N4O4


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. bufalina China 403123 Cai20170220

External Databases


References

  • Alkaloids isolated from Tabernaemontana bufalina display xanthine oxidase inhibitory activity. Phytochemistry, 2019 (PMID 31302343).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Xanthine oxidase inhibitory

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.94
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney 3.9
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 1259.85
    Distribution Blood-Brain Barrier (Central Nervous System) -3.32
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.54
    Plasma Protein Binding 85.58
    Steady State Volume of Distribution 5.13
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Inhibitor
    Excretion Clearance 11.25
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -30.36
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.17
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 8.66
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -2284710.85
    Rat (Acute) 2.89
    Rat (Chronic Oral) 2.29
    Fathead Minnow 2886.01
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 253524.12
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 5.46
    Log(P) 5.93
    Log S -5.85
    Log(Vapor Pressure) -8291.64
    Melting Point 281.7
    pKa Acid -28.63
    pKa Basic 6.19